GlassScriptPhysician profile
Vicki Lee Redpath
NPI 1326570961
$13,872.06
in general payments reported to CMS, 2019-2025
31 companies · $3,338 in 2025
The $3,338 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,813 · 2022: $2,178 · 2023: $3,229 · 2024: $3,315 · 2025: $3,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,340 · Consulting Fee: $524 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,340.47 |
| Consulting Fee | $524.00 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,626.20 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,876.92 | 2021-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $972.84 | 2022-2025 | Tremfya, Stelara |
| Celltrion USA INC. | $802.94 | 2024-2025 | Zymfentra, Vegzelma |
| Celgene Corporation | $543.03 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $537.60 | 2022-2025 | Tremfya, Remicade, Stelara |
| Organon LLC | $453.06 | 2021-2025 | Renflexis, Hadlima |
| Lilly USA, LLC | $422.30 | 2024-2025 | Omvoh |
| Pfizer INC. | $403.18 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.97 | 2021-2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $388.28 | 2021-2024 | Dificid, Zerbaxa |
| E.R. Squibb & Sons, L.L.C. | $369.43 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $307.22 | 2024-2025 | Vowst |
| Amgen INC. | $242.36 | 2022-2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $86.69 | 2021-2023 | Suflave |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $65.67 | 2021-2023 | Echelon Endopath, Echelon Flex, Echelon Circular |
| Kerecis Limited | $54.29 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Medtronic, INC. | $49.08 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $37.42 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $35.74 | 2022 | |
| Nestle Healthcare Nutrition INC. | $28.18 | 2023 | |
| Heron Therapeutics, INC. | $25.21 | 2021 | |
| Intercept Pharmaceuticals, INC. | $21.37 | 2022 | |
| Baxter Healthcare | $20.32 | 2022 | |
| Tela Bio, INC. | $19.33 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Acacia Pharma INC | $17.48 | 2021 | |
| Integra Lifesciences Corporation | $17.38 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.51 | 2024 | |
| Axonics, INC. | $12.98 | 2023 | Axonics |
| Pacira Pharmaceuticals Incorporated | $11.62 | 2021 | |
| Endo Pharmaceuticals INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Redpath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.